Omnipod 6 Improves Time in Range Compared with Omnipod 5

Why It Matters

Improved glycemic control with fewer manual interventions can lower complication risk and enhance quality of life, positioning Omnipod 6 as a competitive edge in the rapidly evolving diabetes‑tech market.

Key Takeaways

• Omnipod 6 met non‑inferiority on safety and efficacy endpoints.
• Time in range rose to 73% vs 70% with Omnipod 5.
• Adults reduced daily bolus doses by ~30% using Omnipod 6.
• No severe hypoglycemia or ketoacidosis reported in 8‑week trial.

Pulse Analysis

The STRIVE trial, presented at the American Diabetes Association Scientific Sessions, provides the first head‑to‑head data for Insulet’s Omnipod 6 algorithm against its predecessor. By employing a crossover design with 132 participants across type 1 and type 2 diabetes, the study isolates the impact of the new control logic while keeping device familiarity constant. The algorithm’s tighter glucose target (100 mg/dL versus 110 mg/dL) translated into a measurable rise in time‑in‑range, a key metric linked to long‑term vascular outcomes, without compromising safety.

Beyond the raw percentages, the trial highlights a shift in user behavior: adults on Omnipod 6 cut daily bolus injections by roughly one‑third, and children reduced bolus frequency similarly during an optional bolus‑optional phase. This reduction reflects the system’s ability to deliver basal insulin more precisely, easing the daily management burden that often drives therapeutic fatigue. Maintaining mean glucose at 151 mg/dL—seven points lower than the Omnipod 5 arm—while keeping severe hypoglycemia at zero underscores the algorithm’s robustness, a critical factor for clinicians wary of closed‑loop adoption.

For the diabetes‑technology market, Omnipod 6 strengthens Insulet’s position against rivals such as Medtronic’s MiniMed 780G and Tandem’s Control‑IQ. The demonstrated efficacy may accelerate payer coverage discussions, especially as the device approaches a fully closed‑loop experience without the need for frequent manual bolusing. As integration with continuous glucose monitors deepens, Omnipod 6 could become a preferred platform for both type 1 and type 2 patients seeking tighter control with less hands‑on management, potentially reshaping the competitive landscape over the next few years.